Your Complete Guide to Global Clinical Research and GCP Compliance
Case Studies: HTA & Payer Evidence Generation That Changed Regulatory or Payer Decisions Introduction The landscape of healthcare is evolving rapidly, with increasing emphasis on the generation of real-world evidence (RWE) to support Health Technology Assessment (HTA) and payer decision-making. Given the regulatory nuances in the US, UK, and EU, it is crucial for clinical…
KRIs, KPIs and Quality Metrics to Improve HTA & Payer Evidence Generation KRIs, KPIs and Quality Metrics to Improve HTA & Payer Evidence Generation In the realm of clinical research, especially concerning Health Technology Assessment (HTA) and payer evidence generation, the implementation of Key Risk Indicators (KRIs), Key Performance Indicators (KPIs), and quality metrics is…
Read More “KRIs, KPIs and Quality Metrics to Improve HTA & Payer Evidence Generation” »
Digital Tools and Data Pipelines to Strengthen HTA & Payer Evidence Generation Digital Tools and Data Pipelines to Strengthen HTA & Payer Evidence Generation Introduction to HTA and Payer Evidence Generation Health Technology Assessment (HTA) plays a critical role in informing healthcare decision-makers about the effectiveness, cost-effectiveness, and overall value of medical technologies and interventions,…
Read More “Digital Tools and Data Pipelines to Strengthen HTA & Payer Evidence Generation” »
Future Trends: Real-World, Digital and Hybrid Evidence in HTA & Payer Evidence Generation As the landscape of clinical research evolves, the integration of real-world evidence (RWE), digital, and hybrid evidence into health technology assessment (HTA) and payer evidence generation becomes increasingly vital. This article provides a comprehensive step-by-step guide for clinical operations, regulatory affairs, and…
How AI and Automation Are Transforming HTA & Payer Evidence Generation How AI and Automation Are Transforming HTA & Payer Evidence Generation The landscape of health technology assessment (HTA) and payer evidence generation is evolving, driven by the rapid advancement of artificial intelligence (AI) and automation technologies. New clinical trials are increasingly incorporating these methodologies…
Read More “How AI and Automation Are Transforming HTA & Payer Evidence Generation” »
Operationalizing HTA & Payer Evidence Generation Across Global Programs Operationalizing HTA & Payer Evidence Generation Across Global Programs Understanding HTA and Payer Requirements in Clinical Research Administration Health Technology Assessment (HTA) and payer engagement are crucial components in the landscape of clinical research administration. They not only evaluate the value of new interventions but also…
Read More “Operationalizing HTA & Payer Evidence Generation Across Global Programs” »
Statistical Approaches to Strengthen HTA & Payer Evidence Generation Statistical Approaches to Strengthen HTA & Payer Evidence Generation In the evolving landscape of clinical evidence generation, the statistical approaches employed in Health Technology Assessment (HTA) and payer evidence generation play a pivotal role, particularly for innovative therapies like mavacamten clinical trial. This comprehensive guide seeks…
Read More “Statistical Approaches to Strengthen HTA & Payer Evidence Generation” »
Governance, Ethics and Compliance Considerations for HTA & Payer Evidence Generation Governance, Ethics and Compliance Considerations for HTA & Payer Evidence Generation In the landscape of clinical trials and evidence generation, the importance of governance, ethics, and compliance cannot be overstated. For healthcare technologies and interventions, Health Technology Assessment (HTA) and payer evidence generation constitute…
Read More “Governance, Ethics and Compliance Considerations for HTA & Payer Evidence Generation” »
Aligning Biostatistics for RWE With Regulatory and HTA Expectations Aligning Biostatistics for RWE With Regulatory and HTA Expectations Real-world evidence (RWE) has emerged as a critical component in the clinical research landscape, particularly for regulatory submissions and health technology assessments (HTAs). This comprehensive guide provides clinical operations, regulatory affairs, and medical affairs professionals with a…
Read More “Aligning Biostatistics for RWE With Regulatory and HTA Expectations” »
Common Biases in Biostatistics for RWE—and How to Correct Them In the field of clinical research, particularly when dealing with Real-World Evidence (RWE), understanding biases in biostatistics is crucial for accurate interpretation of data. RWE derived from observational studies often encounters several biases that can significantly influence study findings. This comprehensive guide aims to equip…
Read More “Common Biases in Biostatistics for RWE—and How to Correct Them” »
Don’t leave empty-handed. Watch practical GMP scenarios, inspection lessons, deviations, CAPA thinking, and real compliance insights on our YouTube channel. One click now can save you hours later.